[LIVER DISORDERS DUE TO TREATMENT WITH PROPIONYL-ERYTHROMYCIN-LAURYLSULFATE (ILOSONE)].
D000469:Alkaline Phosphatase / Q000097:blood*; D001663:Bilirubin; D056486:Chemical and Drug Induced Liver Injury; D004796:Clinical Enzyme Tests; D004342:Drug Hypersensitivity; D004917:Erythromycin; D004918:Erythromycin Estolate; D006506:Hepatitis A; D007565:Jaundice; D008107:Liver Diseases; D008111:Liver Function Tests; D012967:Sodium Dodecyl Sulfate; D014116:Toxicology; D000637:Transaminases
D012967:Sodium Dodecyl Sulfate; D004917:Erythromycin; C028913:dodecyl sulfate; D000637:Transaminases; D000469:Alkaline Phosphatase; D001663:Bilirubin; D004918:Erythromycin Estolate
AMINOTRANSFERASES; BILIRUBIN; BLOOD ALKALINE PHOSPHATASE; DRUG HYPERSENSITIVITY; ENZYME TESTS; ERYTHROMYCIN; HEPATITIS, INFECTIOUS; HEPATITIS, TOXIC; JAUNDICE; LIVER FUNCTION TESTS; TOXICOLOGIC REPORT
LEVERAFFEKSJON UNDER BEHANDLING MED PROPIONYL-ERYTHROMYCIN-LAURYLSULFAT (ILOSONE)